来曲唑治疗绝经后乳腺癌骨转移

Clinical trial of letrozole for postmenopausal patients with bone metastasis in breast cancer

目的:研究来曲唑解救治疗绝经后乳腺癌骨转移的疗效和副作用。方法:36例绝经后乳腺癌骨转移患者给予来曲唑2.5 mg,每日1次,口服至少2月。结果:36例可评价疗效和毒副作用患者中,完全缓解(CR)2例,部分缓解(PR)8例,总有效率占27.7%。稳定(SD)20例占55.5%,其中病情稳定≥6月者11例,临床获益患者(CR+PR+SD)≥6月21例占58.3%,病情进展6例占16.6%。治疗中无严重不良反应。结论:来曲唑治疗绝经后乳腺癌骨转移有一定疗效,药物不良反应轻,患者容易耐受。

Purpose: To evaluate the efficacy and adverse effects of letrozole for postmenopausal breast cancer patients with bone raetastases. Methods: Thity-six breast cancer patients with bone metstases received 2. 5 mg tablet letrozole every day. for at least two months. Results: In the 36 patients who were evaluable for efficacy and toxicity, the complete response rate (CR) , partial response rate ( PR) , disease stabilization rate ( SD) and progressive disease rate ( PD) were respectively 5.5% , 22. 2% , 55. 5% and 16. 6% . The clinical benefit rate ( CR + PR + SD ≥ 6 months ) was 58. 3% (21/36) with 11 patients (30. 5%) having SD for at least 6 months . Conclusions: Letrozole is a well tolerated agent with reasonable efficacy but low toxicity for postmenopausal breast cancer patients with bone metastases.